134 related articles for article (PubMed ID: 23584480)
1. RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
Zhu Y; Das K; Wu J; Lee MH; Tan P
Oncogene; 2014 Mar; 33(12):1527-37. PubMed ID: 23584480
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
3. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
5. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs).
Mackmull MT; Iskar M; Parca L; Singer S; Bork P; Ori A; Beck M
Mol Cell Proteomics; 2015 May; 14(5):1350-60. PubMed ID: 25755299
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells.
Lee JH; Jeong EG; Choi MC; Kim SH; Park JH; Song SH; Park J; Bang YJ; Kim TY
Mol Cells; 2010 Aug; 30(2):107-12. PubMed ID: 20680488
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
11. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
Ungerstedt JS; Sowa Y; Xu WS; Shao Y; Dokmanovic M; Perez G; Ngo L; Holmgren A; Jiang X; Marks PA
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):673-8. PubMed ID: 15637150
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
Lin KT; Wang YW; Chen CT; Ho CM; Su WH; Jou YS
Clin Cancer Res; 2012 Sep; 18(17):4691-701. PubMed ID: 22811583
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines.
Hentati-Kallel M; Le Jan S; Bernard P; Antonicelli F; Trussardi-Régnier A
Int J Oncol; 2017 Feb; 50(2):717-726. PubMed ID: 28035377
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
17. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
[TBL] [Abstract][Full Text] [Related]
18. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors: roles of DNA damage and repair.
Robert C; Rassool FV
Adv Cancer Res; 2012; 116():87-129. PubMed ID: 23088869
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]